Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt

Parasitology Research

Volumn 102, Issue 4, 2008, Pages 631-633

  Barduagni, Paolo ^a   Hassanein, Yehia ^b   Mohamed, Mostafa ^b   Wakeel, Aly El ^c   Sayed, Mabrouk El ^c   Hallaj, Zuhair ^d   Curtale, Filippo ^e  

^a Ministry of Foreign Affairs   (Italy)

^b MINISTRY OF HEALTH   (Egypt)

^c Healthy Mother Healthy Child Project   (Egypt)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Malattie Infettive   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRICLABENDAZOLE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; EGYPT; ENDEMIC DISEASE; EXCRETION; FASCIOLA; FASCIOLIASIS; FEMALE; HUMAN; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHOOL CHILD; TREATMENT DURATION; WORM EGG;

ADOLESCENT; ADULT; ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; CHILD; EGYPT; FASCIOLA; FASCIOLIASIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARASITE EGG COUNT; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TREATMENT OUTCOME;

ANIMALIA; FASCIOLA; PARAGONIMUS; SCHISTOSOMA MANSONI; TREMATODA;

EID: 39749088105     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-007-0802-6     Document Type: Article

References (12)

1. Bundy DAP, Hall A, Medley GF, Savioli L (1992) Evaluating measures to control intestinal parasitic infections. World Health Stat Q 45:168-179
2. Calvopina M, Guderian RH, Paredes W, Cooper PJ (2003) Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. Trans R Soc Trop Med Hyg 97:451-454
3. Curtale F, Hassanein YAW, El Wakeel A, Barduagni P, Savioli L (2003) The school health programme in Behera: an integrated helminth control programme at governorate level in Egypt. Acta Trop 86:295-307
4. El Sayed MH, Allam AF, (1997) effect of triclabendazole on the tegument of Schistosoma mansoni: a scanning electron microscopic study. J Egypt Soc Parasitol 7::43-152
5. Keiser J, El Ela NA, El Lakkany N, Diab T, Chollet J, Utzinger J, Barakat R (2006) Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in mouse model. Am J Trop Med Hyg 75:287-291
6. Khalil SS (2000) On the schistosomicidial effect of triclabendazole: an experimental study. J Egypt Soc Parasitol 30:799-808
7. Mansoury ST (1997) Effect of two trematodicidal drugs on the morphology and tegumentary ultrastructure of Schistosoma mansoni. J Egypt Soc Parasitol 27:233-241
8. Millán JC, Mull R, Freise S, Richter J, For the Triclabendazole Study Group (2000) The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 63:264-269
9. Polman K, Stelma FF, Le Cessie S, De Vias SJ, Falcao Ferreira ST, Tallia I, Deelder AM, Gryseels B (2002) Evaluation of the patterns of Schistosoma mansoni infection and re-infection in Senegal, from faecal egg counts and serum concentrations of circulating anodic antigen. Ann Trop Med Parasitol 96:679-689
10. WHO (1994) Bench aids for the diagnosis of intestinal parasites. World Health Organization, Geneva
11. WHO (1995) WHO model prescribing information. Drugs used in parasitic diseases., 2nd edn. World Health Organization, Geneva
12. WHO (1998) Triclabendazole and fascioliasis-a new drug to combat an age-old disease. World Health Organization, Geneva (Fact sheet no. 191)